MedTrace Logo

AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19

NCT04516759 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2022-04-25

Study results available
· View outcomes & findings →

Summary

The ARCADIA Trial is a randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with either Type 1 or Type 2 diabetes, hospitalised with COVID-19.

Conditions

  • Covid19

Interventions

DRUG

AZD1656

50mg film-coated tablets (at daily dose of 100mg BID)

OTHER

Placebo

Matched placebo tablets

Sponsors & Collaborators

  • St George Street Capital

    lead OTHER

Principal Investigators

  • Kieran McCafferty, MD · Barts & The London NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-12
Primary Completion
2021-04-25
Completion
2021-05-12

Countries

  • Czechia
  • Romania
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04516759 on ClinicalTrials.gov